/ Lupin Launches Generic Vigamox Ophthalmic Solution In The US ~ Ways2Capital|Stock Tips|Stock Market Tips|Intraday Stock Tips|Stock Trading Tips|NSE BSE Tips

Wednesday, 5 July 2017

Pharma major, Lupin Limited announced the launch of its Moxifloxacin Hydrochloride Ophthalmic solution USP, 0.5% (base) having received an approval from the USFDA earlier.

Lupin’s Moxifloxacin Hydrochloride Ophthalmic solution USP, 0.5% (base), is an AT1 rated generic equivalent of Novartis Pharma Corp’s Vigamox Ophthalmic solution. It is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the organisms.

Vigamox Ophthalmic solution had US sales of USD 267.9 million (IMS MAT March 2017). Lupin was trading in positive territory at Rs 1052.5 per share up by Rs 8.6 per share or 0.8%. It is outperforming the Nifty Pharma index on Wednesday.

For Quick Trial – 8962000225 ✔
or mail us here: info@ways2capital.com
✆ - 0731-6626222 | Toll Free - 1800-3010-2007 
Give a Missed Call for Free Trial - 09699997717